Xtant Medical said today it inked a distribution deal with Vivex Biomedical to distribute its OsteoVive cellular bone allograft. The new agreement will allow Xtant to enter the cellular bone graft market which the company said is estimated to be between $252 million in 2015 and $400 million in 2019. “Vivex is enthusiastic about teaming up with […]
Vivex Biomedical
Vivex Biomedical raises $6.6m in Series A
Vivex Biomedical reported it pulled in $6.6 million in a Series A equity round of convertible preferred stock, according to an SEC filing. The company is focused on cellular therapies for treating orthopedic, spinal, wound and soft tissue indications, according to its website. Marietta, Ga.-based Vivex Biomedical develops a number of regenerative medical products, including […]